- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04767464
Feasibility of Providing a Purpose Renewal Intervention for Cancer Survivors Via Virtual Groups (CC-V)
November 10, 2023 updated by: Mary Radomski
The Compass Course (CC) is a group intervention designed for individuals with Breast Cancer.
Over the course of 8 face-to-face group sessions, the CC is designed to help participants reclaim a sense of self-grounded purpose in daily life, defined as intentional use of time and energy in ways that align with one's values, strengths, and sources of personal meaning (e.g., inner compass) in the moments that compose a day.
Because of COVID-19, in-person groups are discouraged and so we need to identify new ways to provide group-based interventions that are feasible and efficacious.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55447
- Abbott Northwestern Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Able to attend intervention sessions for 9 weeks on Monday or Tuesday afternoons (4:30 - 6:30 pm) starting Monday, April 5, 2021
- 25 years of age or older
- Completed chemotherapy and/or radiation treatment for Stage 0, 1, 2, or 3 breast cancer at least 2 months prior to participating in the Compass Course intervention
- English speaking
- Graduated from high school
- Able to see, hear, speak (with or without assistive devices)
- Able to provide own transportation to sessions
- Willing and able to commit to attend all 8 intervention sessions
- Access to computer or tablet and adequate internet connection to participate in video conference
Exclusion Criteria:
- Stage 4 breast cancer or any other cancer
- Actively receiving chemotherapy or radiation treatments for cancer. (However, patients may be on Herceptin and/or endocrine treatment and participate in the study.)
- History of neurologic disorder (such as stroke or brain injury) with residual impairments that likely interfere with learning
- Any medical condition (physical or mental health) that interferes with the performance of everyday activities and roles.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Compass Course
Virtual Compass Course
|
The Compass Course is an 8-session group course designed to address purpose in life of those with Breast Cancer.
Enrollment in this arm will involve participation in the Compass Course virtually.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Scales of Psychological Wellbeing
Time Frame: Through Study Completion (about 4 Months)
|
A widely-used self-report questionnaire that was designed to measure 6 theoretically motivated dimensions of psychological well-being (autonomy, environmental mastery, personal growth, positive relations with others, purpose in life, self-acceptance).
|
Through Study Completion (about 4 Months)
|
|
Change in Meaning in Life Questionnaire
Time Frame: Through Study Completion (about 4 Months)
|
A 10-item questionnaire designed to measure 2 dimensions of meaning in life: Presence of Meaning (how much respondents feel their lives have meaning) and Search for Meaning (how much respondents strive to find meaning and understanding in their lives).
|
Through Study Completion (about 4 Months)
|
|
Change in Engagement in Meaningful Activities survey
Time Frame: Through Study Completion (about 4 Months)
|
A 12-item self-report questionnaire designed to measure the extent to which a person experiences meaningfulness in his/her daily life activities.
|
Through Study Completion (about 4 Months)
|
|
Change in Purpose Status Question
Time Frame: Through Study Completion (about 4 Months)
|
A single forced-choice self-report screener question that we developed in order to characterize existential distress related to purpose in life.
|
Through Study Completion (about 4 Months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Beck Depression Inventory -- II
Time Frame: Through Study Completion (about 4 Months)
|
A 21-question, widely-used self-report rating inventory that measures characteristic attitudes and symptoms of depression.
|
Through Study Completion (about 4 Months)
|
|
Change in State-Trait Anxiety Inventory
Time Frame: Through Study Completion (about 4 Months)
|
A self-report questionnaire composed of 20 state and 20 trait statements related to anxiety.
We will use the 20-item State inventory (1-4 scale).
|
Through Study Completion (about 4 Months)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Mary V Radomski, OTR/L, PhD, Senior Scientific Advisor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2021
Primary Completion (Actual)
February 15, 2022
Study Completion (Actual)
November 7, 2023
Study Registration Dates
First Submitted
February 11, 2021
First Submitted That Met QC Criteria
February 22, 2021
First Posted (Actual)
February 23, 2021
Study Record Updates
Last Update Posted (Estimated)
November 14, 2023
Last Update Submitted That Met QC Criteria
November 10, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CKRC2021-CCV
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Colorado, DenverCompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
Clinical Trials on Compass Course
-
Mary RadomskiCompletedConcussion; SyndromeUnited States
-
Columbia UniversityDepartment for International Development, United Kingdom; International Rescue...CompletedDomestic Violence | Sexual Assault | Interpersonal Relations | Marital StatusUnited States
-
VA Office of Research and DevelopmentCompletedTraumatic Brain Injury | Post-Traumatic Stress DisorderUnited States
-
Seattle Children's HospitalLife Sciences Development FundUnknown
-
King's College LondonKing's College Hospital NHS TrustNot yet recruitingDepression | Multiple Sclerosis | Anxiety
-
King's College LondonSouth London and Maudsley NHS Foundation TrustCompletedDepression | Quality of Life | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Diabetes | Diabetes Mellitus, Type 1 | Anxiety | Loneliness | Distress, Emotional | Diabetes Distress | Social FunctioningUnited Kingdom
-
Women and Infants Hospital of Rhode IslandNational Institute of Nursing Research (NINR); Brown UniversityRecruitingPerinatal Mental HealthUnited States
-
King's College LondonGuy's and St Thomas's NHS Foundation Trust; Crohn's and Colitis UKRecruitingPsychological Distress | IBD | Treatment of Illness-related Distress in IBDUnited Kingdom